Bone Biologics Corporation
BBLG
$0.55
-$0.01-1.07%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.17M | 2.22M | 2.17M | 2.15M | 2.14M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.06M | 3.00M | 3.24M | 4.06M | 4.29M |
| Operating Income | -3.06M | -3.00M | -3.24M | -4.06M | -4.29M |
| Income Before Tax | -2.89M | -2.86M | -3.11M | -3.95M | -4.22M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.89 | -2.86 | -3.11 | -3.95 | -4.22 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.89M | -2.86M | -3.11M | -3.95M | -4.22M |
| EBIT | -3.06M | -3.00M | -3.24M | -4.06M | -4.29M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -1.61 | -2.51 | -4.00 | -7.30 | -21.13 |
| Normalized Basic EPS | -1.01 | -1.57 | -2.50 | -4.56 | -6.34 |
| EPS Diluted | -1.61 | -2.51 | -4.00 | -7.30 | -21.13 |
| Normalized Diluted EPS | -1.01 | -1.57 | -2.50 | -4.56 | -6.34 |
| Average Basic Shares Outstanding | 7.19M | 5.95M | 4.69M | 3.30M | 1.79M |
| Average Diluted Shares Outstanding | 7.19M | 5.95M | 4.69M | 3.30M | 1.79M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |